Celgene Stock

CELG

Delayed Nasdaq Other stock markets 04:00:00 2019-11-20 pm EST			5-day change	1st Jan Change
108.24 ^USD	+0.10%		-1.97%	+68.89%

23-06-14	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
21-09-07	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI

News in other languages: Celgene

21-04-07	DGAP-WpÜG: Angebot zum Erwerb / Zielgesellschaft: ; Bieter: qqqqq
21-03-25	Leonteq wird neue Emittentin an der BX Swiss AG im Segment «deriBX»
21-02-02	BX Swiss AG startet Handel in neuem Bondsegment
20-07-07	Die BX Swiss AG erhält von der FINMA die Zulassung zur Führung des Schweizer Beraterregisters
20-07-03	Möbel Markt mömax wird neuer Ankermieter im Rüti Center in Pratteln

More news

Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.9%); - other (0.1%): cellular therapy products and biological materials for implants, for tissue and organ treatments, and for therapeutic product development. Net sales are distributed geographically as follows: the United States (65.6%), Europe (24.7%) and other (9.7%).

Employees

Sector

More about the company

Market Cap	77.04B 66.76B 62.5B 57.03B 107B 7,348B 109B 733B 287B 3,678B 289B 283B 12,269B	P/E 2017	28.7x	P/E 2018	11.6x
Enterprise Value	91.26B 79.08B 74.03B 67.55B 127B 8,704B 129B 868B 340B 4,357B 343B 335B 14,534B	EV / Sales 2017	6.61x	EV / Sales 2018	3.86x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

23-06-14	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
21-09-07	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI
21-06-21	Celgene Corporation Will Grant Sun Pharmaceutical Industries Limited A License to Celgene's Patents Required to Manufacture and Sell Certain Limited Quantity	CI
21-02-22	Celgene Corporation Issues Notice of Redemption of Notes	CI
21-02-04	Bristol-Myers Squibb Company and Celgene Corporation Announce Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion	CI
21-01-04	Ikena Oncology, Inc. announced that it has received $120 million in funding from a group of investors	CI
20-12-22	Amgen : Signs Licensing Agreement With Medicines Development for Global Health	MT
20-11-05	Bristol Myers Squibb : Q3 Results Beat Estimates; Raises 2020 EPS Outlook	MT
20-09-22	Silverback Therapeutics, Inc. announced that it has received $84.999996 million in funding from a group of investors	CI
20-09-21	Silverback Therapeutics, Inc. announced that it expects to receive $84.999996 million in funding from a group of investors	CI
20-03-25	Agios Pharmaceuticals, Inc. Provides Update on 2016 Collaboration Agreement with Celgene	CI
20-03-10	Silverback Therapeutics, Inc. announced that it has received $68.400013 million in funding from a group of investors	CI
20-03-04	Pulmonary Fibrosis Foundation Launches Industry Consortium to Identify Biomarkers in Pulmonary Fibrosis	CI

23-02-28	BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)	AQ
22-08-24	Not What The Doctor Ordered: Authorisation Application Withdrawn For Pharma Patent Settlement In Australia	AQ
22-07-29	Authorisation request for proposed settlement between pharmaceutical companies withdrawn	AQ
22-02-24	BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)	AQ
21-08-04	Celgene : Sun Pharma And Celegene Settle Patent Dispute Over Lenalidomide (Revlimid®)	AQ

	2017	2018
Net sales	13B 11.27B 10.55B 9.63B 18.11B 1,240B 18.42B 124B 48.46B 621B 48.82B 47.76B 2,071B	15.28B 13.24B 12.4B 11.31B 21.29B 1,457B 21.64B 145B 56.95B 730B 57.38B 56.13B 2,434B
Net income	2.94B 2.55B 2.39B 2.18B 4.1B 280B 4.16B 27.97B 10.96B 140B 11.04B 10.8B 468B	4.05B 3.51B 3.28B 3B 5.64B 386B 5.73B 38.49B 15.08B 193B 15.19B 14.86B 644B
Net Debt	3.79B 3.29B 3.08B 2.81B 5.28B 362B 5.37B 36.08B 14.14B 181B 14.24B 13.93B 604B	14.22B 12.32B 11.54B 10.53B 19.81B 1,356B 20.14B 135B 53B 679B 53.4B 52.23B 2,265B

Celgene Stock

Stocks

CELG

Valuation: Celgene

Latest news : Celgene

Press Releases: Celgene

News in other languages: Celgene

Quotes and Performance

Financials

Company Profile